SEP 21, 2015 2:31 PM PDT

Enzyme Could Fight Cancer and Autoimmune Diseases

WRITTEN BY: Ilene Schneider

Scientists at The Scripps Research Institute have discovered a critical role played by an enzyme in cancer and autoimmune diseases. Their findings could help in the development of therapy for the diseases.
Role of enzyme in triggering diseases could lead to therapy. 
The scientists have found that the enzyme receptor-interacting serine-threonine kinase-3 (RIPK3) has a role not previously known: sending messages between the mitochondria "powerhouses" of the cells and the immune system, according to an article published in the journal Nature Communications and reported by Yvette Brazier in Medical News Today. 
 
According to the research, the communication performed by RIPK3 has two roles: first, to launch immune responses against tumors, and second, to regulate inflammatory responses that may result in autoimmune diseases. Scientists already knew that RIPK3 controlled the induction of necroptosis, a type of programmed cell death. While necroptosis protects the body from harmful mutations and infections, its role in the immune system is only now becoming understood.
 
In order to gain a better understanding of RIPK3, the Scripps researchers studied RIPK3-deficient mice. They determined that RIPK3 seems to regulate the activation of natural killer T cells (NKTs). These NKTs are immune cells that have a function in both the development of autoimmune diseases and the destruction of cancer.
 
Researchers believe that RIPK3 regulates the activity of a mitochondrial enzyme known as PGAM5, and this, in turn, initiates the expression of inflammatory cytokines in NKTs. The scientists now hope that understanding this pathway will help to achieve better ways to control NKTs in order to attack tumors. They also think that understanding the pathway can also make it possible to disrupt it in order to block inflammation. When the researchers detected the gene for RIPK3, or blocked other parts of the pathway, they discovered that they could actually protect mice from acute liver damage. They believe that this might mean that there is a role for RIPK3 in autoimmune diseases.
 
According to the Scripps Research Institute (TSRI) Assistant Professor of Immunology Young Jun Kang, who collaborated on the study with the lab of TSRI Institute Professor Richard A. Lerner -- who is also Lita Annenberg Hazen Professor of Immunochemistry, "This finding could be helpful for developing strategies to target cancer and inflammatory diseases."
 
The next step will be to focus on understanding the details of this new signaling pathway. Once the scientists have reached that stage, they think the research will pave the way for new therapies to either enhance its cancer-killing role or reduce its role in inflammation.

About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
SEP 02, 2021
Cancer
When Cholesterol Doesn't Kill Cancer, it Makes it Stronger!
SEP 02, 2021
When Cholesterol Doesn't Kill Cancer, it Makes it Stronger!
High cholesterol is associated with an increased risk of several types of cancer, and cancer patients with high choleste ...
OCT 26, 2021
Immunology
Two Different Arms, Twice the Cancer-Killing Potential?
OCT 26, 2021
Two Different Arms, Twice the Cancer-Killing Potential?
Our immune system has developed an arsenal of sophisticated molecular weapons to defend us against the continuous barrag ...
NOV 22, 2021
Cancer
A New Treatment Option for Patients with Cancer in the Eye
NOV 22, 2021
A New Treatment Option for Patients with Cancer in the Eye
Uveal melanoma (UM) is a rare malignancy characterized by the formation of cancer cells in the tissues of the eye. UM be ...
NOV 29, 2021
Cancer
An Amino Acid Can Improve Radiation Therapy for Metastatic Brain Cancer
NOV 29, 2021
An Amino Acid Can Improve Radiation Therapy for Metastatic Brain Cancer
There are 20 different amino acids that the human body uses to generate proteins.  Amino acids form chains called p ...
DEC 06, 2021
Cancer
Young Patients with Lymphoma Benefit from Chemotherapy Combination Treatment
DEC 06, 2021
Young Patients with Lymphoma Benefit from Chemotherapy Combination Treatment
The most common form of non-Hodgkin lymphoma is diffuse large B-cell lymphoma (DLBCL). DLBCL is a fast-growing cancer th ...
DEC 13, 2021
Cancer
Mistletoe: Parasite, Symbol of Romance, or Cancer Treatment?
DEC 13, 2021
Mistletoe: Parasite, Symbol of Romance, or Cancer Treatment?
As we approach the winter season, decorative swigs of mistletoe are starting to make their holiday debut.  You may ...
Loading Comments...